Oruka Therapeutics (ORKA) stock is drawing fresh attention after positive interim Phase 2a data for lead antibody ORKA-001 in moderate to severe plaque psoriasis, as well as an expanded IL-23 license that now clearly covers inflammatory bowel disease.

The latest data and licensing news come after a sharp move in the share price, with a 1-day share price return of 8.88% and a 7-day share price return of 7.42%. However, the 30-day share price return is down 9.67%. Even so, the 90-day share price return of 88.90% and year-to-date share price return of 120.30%, alongside a 1-year total shareholder return of over 4x, point to strong momentum building around the story.

If this kind of biotech re-rating has your attention, it can be useful to scan for other healthcare stocks riding similar interest in new treatments and platforms through the 40 healthcare AI stocks

With interim data, an expanded IL-23 license and a stock that has already delivered a more than 4x 1-year total return, the key question now is whether Oruka is still mispriced or if the market is already pricing in future growth.

Price to Book of 7.8x: Is It Justified?

Oruka is trading on a P/B of 7.8x, which stands well above both direct peers and the broader US biotechs industry, even as the company remains unprofitable.

The P/B ratio compares the company’s market value to its book value, so a higher figure often reflects strong expectations around future assets, such as successful drug candidates or valuable intellectual property. For a clinical stage biopharma company with no meaningful revenue and a net loss of $94.19m, a rich P/B can indicate that investors are placing considerable weight on the current pipeline and licensing deals rather than on today’s financials.

In this context, Oruka’s 7.8x P/B sits well above the peer average of 3.9x and the US biotechs industry average of 2.4x. This suggests the stock is pricing in a far more optimistic outlook than the sector in general. With no DCF fair value available and a value score of 0, the market is leaning heavily on sentiment around ORKA-001, ORKA-002 and the broader IL-23 and IL-17 franchise rather than on conventional balance sheet metrics.

Result: Price-to-book of 7.8x (OVERVALUED)

However, there are clear pressure points here, including clinical risk around ORKA-001 and ORKA-002, and the company’s US$94.19m net loss with no revenue yet.

Next Steps

With sentiment clearly split between excitement and caution, it makes sense to move quickly, review the key data points and weigh the 5 important warning signs.

Looking for more investment ideas?

If Oruka has sharpened your focus on where capital goes next, it is worth lining up a few more candidates that fit clear, high conviction themes.

• Target potential turnaround stories by scanning 24 elite penny stocks with strong financials that already show solid underlying financial strength.
• Hunt for quality at a reasonable price by reviewing the 47 high quality undervalued stocks that combine robust cash flows with supportive balance sheets.
• Prioritise resilience first by checking out the 64 resilient stocks with low risk scores that score well on stability and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.